Drug Profile
Research programme: ruthenium-based chemotherapy - Oncosense
Alternative Names: MMI 4403; ONCO 4402; ONCO 4403; ONCO 4417; Ruthenium 4403; Ruthenium 4417Latest Information Update: 04 May 2010
Price :
$50
*
At a glance
- Originator University of Edinburgh
- Developer Oncosense
- Class Organometallic compounds
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Sep 2009 Discontinued - Preclinical for Cancer in United Kingdom (IV)
- 29 Mar 2007 Preclinical development is ongoing
- 06 Oct 2003 Preclinical trials in Cancer in United Kingdom (IV)